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Although anticonvulsant drugs are the 
mainstay of therapy for epilepsy, their 
mechanisms of action remain uncertain for 
several reasons. First, most anticonvulsant 
compounds have been shown to have mul- 
tiple physiological, biochemical, and phar- 
macological actions. It has been difficult, 
therefore, to determine which specific drug 
actions produce clinical effects. Second, 
investigation has often been performed on 
isolated peripheral or invertebrate neuronal 
or muscle preparations or on neurons in 
the intact vertebrate central nervous sys- 
tem. In the former case, the number of 
drug actions that can be studied is limited, 
since the pharmacology of these cells is 
quite unlike that found in the vertebrate 
central nervous system. In the latter case, 
the preparation is technically difficult to 
study and, therefore, limited experimental 
control is possible. Third, investigators 
have identified single actions of anticon- 
vulsants and suggested a role in anticon- 
vulsant action without determining if the 
drug effect is produced at concentrations 
achieved in the central nervous system 
during clinical use. Finally, anticonvul- 
sants are often studied at concentrations 
achieved in serum during clinical use. 
However, for anticonvulsants that are pro- 
tein bound, it is important to use thera- 
peutic free-serum concentrations, since 
Michigun 
cerebrospinal fluid drug levels reflect 
free, not total, serum drug concentrations. 
We have employed an in vitro mamma- 
lian neuronal preparation to study anticon- 
vulsant drug action. Mouse spinal cord 
neurons in primary dissociated cell culture 
develop electrical excitability, synaptic 
connectivity, and postsynaptic chemosen- 
sitivity to a variety of putative neurotrans- 
mitters ( 1,2). Stable intracellular recordings 
can be made from individual neurons for 
several hours, and drugs and neurotrans- 
mitters can be applied by iontophoresis, 
local pressure ejection, or superfusion of 
the entire culture. Furthermore, with this 
neuronal preparation, it is possible to apply 
known concentrations of anticonvulsants 
directly to neurons in serum-free medium, 
thus  obviating many pharmacokinetic 
problems of whole animal studies (serum 
protein binding, blood-brain barrier, and 
drug metabolism). In this paper we will re- 
view our  investigations of barbiturate 
mechanisms of action and present recent 
studies of phenytoin actions. 
Barbiturate Actions 
Long-acting barbiturates such as pheno- 
barbital (PhB) and mephobarbital are use- 
ful as chronic anticonvulsants since they 
have minimal sedative action at therapeutic 
concentrations. Intermediate- and short- 
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acting barbiturates such as pentobarbital 
(PB), thiopental, or amobarbital are also 
effective anticonvulsants, but cannot be 
used clinically due to their prominent seda- 
tive effects. What is the basis for this differ- 
ence in action among these barbiturates? 
To assess barbiturate actions on physio- 
logical neuronal activity, we determined the 
effect of PhB and PB on normal spontane- 
ous activity (3) (Fig. 1). Spontaneous activ- 
ity of spinal cord neurons in cell culture 
consists of a random admixture of excitato- 
ry and inhibitory postsynaptic potentials 
and spontaneous action potentials. Both 
PhB and PB produced dose-dependent re- 
duction in spontaneous activity, resulting in 
an increasing percentage of quiescent 
neurons at increasing barbiturate concen- 
trations. PB was substantially more potent 
than PhB, increasing the percentage of 
quiescent neurons from 0 to 100% over 
concentrations of 100-500 p M  (ED,,, 
250 p M ) .  PhB produced a similar effect 
at higher concentrations of 500-2,500 p M  
(ED,,,, 900 p M ) .  PB produces anesthesia 
at brain levels of about 100-200 p M ,  and 
thus production of 20-30% quiescent 
neurons should correlate with anesthesia. 
Anticonvulsant action would have to occur 
at  much lower concentrations to  avoid 
sedative toxicity. 
As a model of anticonvulsant action, we 
investigated the effect of barbiturates on 
bicuculline (B1CUC)-induced paroxysmal 
activity (3) .  BICUC is a convulsant that 
antagonizes GABA responses (4-6) by 
competing with GABA to bind to GABA 
receptors (7,8). In addition, at somewhat 
CON 200,uM 500,uM I mM 
PhB 
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FIG. 1. Phenobarbital (PhB, triangles) and pentobarbital (PB, circles) reduced spontaneous activity. Spontane- 
ous activity was recorded from spinal cord neurons in control medium (phosphate buffered saline, PBS) and in 
PBS containing barbiturates. Specimen records are intracellular recordings made with glass micropipettes filled 
with 4 M  potassium acetate displayed on a rectilinear polygraph. Each point in the graph represents the mean 74- 
silent neurons obtained from 4 to 7 neurons (total of 22 for PB and 18 for PhB). CON, control. (From Schulz 
and Macdonald ( 3 ) .  with permission.) 









higher concentrations,  BICUC reduces 
membrane potassium conductance (9,lO). 
When added to medium bathing spinal cord 
neurons in cell culture, BICUC produces 
large, randomly occurring depolarizations 
that evoke volleys of action potentials (5 ,9 ) .  
These paroxysmal depolarizing events  
(PDE) appear to be similar to convulsant- 
induced paroxysmal bursting in spinal 
motor neurons (11) and to  convulsant- 
induced paroxysmal depolarization shifts 
recorded in cortical neurons (12,131. When 
BICUC was added at 40 p M ,  all neurons 
developed PDE (9 ) .  Both PhB and PB 
(25-500 p M )  abolished PDE in a dose- 
dependent fashion (Fig. 2).  PB (ED,,, 75 
pM) was slightly more potent than PhB 
(ED,,,, 90 p M ) ,  but both drugs restored 
normal spontaneous activity. Therapeutic 
anticonvulsant serum levels of PhB vary 




since PhB is about 50% protein bound, free 
PhB levels would be in the range of about 
20 to 80 p M .  Thus, PhB (and PB) reversed 
convulsant-induced paroxysmal activity 
and restored normal spontaneous activity at 
clinically relevant concentrations. 
What are the bases for barbiturate anti- 
convulsant, sedative-hypnotic, and anes- 
thetic actions? Barbiturates have multiple 
actions on both synaptic and nonsynaptic 
membranes (Table 1). Barbiturates act  
(a) postsynapt ical ly  to enhance GABAergic 
inhibition (3,14- 19),  to  reduce  gluta- 
minergic (15,17- 19) and cholinergic (20,  
21) excitation, and to  directly activate 
membrane GABA receptor-coupled chlo- 
ride ion channels (3,15,19); (b) presynap-  
tically to reduce release of neurotransmitters 
(22-25)  including GABA (26,271, glutamate 
(27-29), aspartate (28-30), acetylcholine 
(28,31-34), and norepinephrine (35); and 
100pM 200pM 
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TABLE 1. Barbiturate actions 
'. 
I I 1 I I 
Alteration of postsynaptic neurotransmitter action 
Enhancement of GABA-mediated inhibition 
Antagonism of excitatory synaptic transmission 
Direct enhancement of membrane chloride ion conductance 
Reduction of presynaptic calcium entry and neurotransmitter release 
Reduction of nonsynaptic membrane sodium and potassium ion conductances 
- 
(c) nonsynaptically to reduce sodium and 
potassium conductances (36-38). 
To investigate postsynaptic barbiturate 
actions on neurotransmitter responses, we 
determined the effect of barbiturates on 
GABA, glycine, P-alanine, and glutamic 
acid responses  evoked o n  spinal cord 
neurons (3,18,19). Both PhB (20-500 p M )  
CON 50,uM 
. .  .GABA. 
PhB 
and PB (10-400 p M )  augmented GABA re- 
sponses at  low concentrations without al- 
tering glycine or  p-alanine responses, with 
PB having a slightly lower EDso (50 p M )  
than PhB (75 p M )  (Fig. 3). Both PhB and 
PB antagonized glutamic acid responses at 
barbiturate concentrat ions effective in  
augmenting GABA responses. Thus, both 
CON 100,uM 
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PhB and PB modulated postsynaptic amino 
acid responses at concentrations which re- 
versed BICUC-induced PDE and which are 
achieved in the central nervous system 
when serum barbiturate concentrations are 
therapeutic. It is therefore likely that bar- 
biturates have anticonvulsant action due to 
augmentation of postsynaptic GABAergic 
inhibition, as well as to antagonism of post- 
synaptic glutaminergic excitation. 
In addition, both PhB and PB were 
shown to reduce calcium-dependent action 
PhB 
potential duration (39) and to increase 
membrane chloride ion conductance (3,191 
(Fig. 4). Release of neurotransmitter is cal- 
cium dependent (40), requiring entry of cal- 
cium through voltage-dependent presynaptic 
calcium channels (40-42). Since barbitu- 
rates reduce calcium-dependent action po- 
tential duration (39) and calcium uptake by 
synaptosomes (43-45), it is probable that 
they block neurotransmitter release by re- 
ducing presynaptic voltage-dependent cal- 
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FIG. 4. Dose-dependency of phenobarbital (PhB, top) and pentobarbital (PB,  bottom) enhancement of GABA 
responses (circles), reduction of calcium-dependent action potentials (triangles), and membrane depolariza- 
tion (mV) (squares). (From Heyer and Macdonald (39), with permission.) 
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chloride ion conductance produced by bar- 
biturates was blocked by the GABA an- 
tagonists penicillin and picrotoxin (19), 
suggesting that the barbiturates bound to 
GABA receptors. Increasing postsynaptic 
membrane chloride ion conductance would 
produce membrane hyperpolarization and a 
decrease in membrane excitability. PhB 
produced these actions only at high con- 
centrations, reducing calcium-dependent 
action potential duration from 100 to 5,000 
yM (ED,,, 900 yM) (39) and increasing 
chloride ion conductance from 500 to 4,000 
p M  (3) (Fig. 4, top). PB was much more 
potent in both actions, reducing calcium- 
dependent action potential duration from 25 
to 600 p M  (ED,,, 170 y M )  and increasing 
chloride ion conductance from 100 to 500 
p M  (Fig. 4, bottom). For both barbiturates, 
reduction of calcium-dependent action po- 
tential duration and increase in membrane 
chloride ion conductance correlated with 
reduction of spontaneous activity (Figs. 1 
and 4). From these data, we concluded that 
sedative-hypnotic actions of barbiturates 
may be due to slight reduction of neuro- 
transmitter release in addition to modula- 
tion of postsynaptic neurotransmitter re- 
sponses. Anesthesia may be produced by 
a larger reduction of neurotransmitter re- 
lease, in addition to modulation of post- 
synaptic neurotransmitter responses and 
direct membrane hyperpolarization. Finally, 
the only difference between anticonvulsant 
and anesthetic barbiturates is the dose- 
dependency of these actions. PhB has a 
relatively large therapeutic index between 
drug concentrations producing postsynaptic 
modulation of neurotransmitter responses 
and those producing reduction of presynap- 
tic neurotransmitter release and postsynap- 
tic membrane hyperpolarization (Fig. 4, 
top). For PB, there is a poor therapeutic 
index (Fig. 4, bottom). 
Phenytoin Actions 
Phenytoin (PT) is useful in the manage- 
ment of a wide variety of partial and 
generalized seizure types similar to those 
responsive to phenobarbital. However, PT 
has less sedative action than the barbitu- 
rates. The mechanism of PT anticonvulsant 
action is unclear. PT limits generalization of 
seizures without suppressing seizure foci, 
and thus is unlike barbiturates, which ele- 
vate seizure threshold (46). PT and PhB 
also have different effectiveness against 
seizures produced in experimental animals. 
PT is effective against maximal elec- 
troshock seizures (MES) but ineffective 
against pentylenetetrazol (PTZ) seizures; 
PhB is more effective against PTZ seizures 
than against MES (47,48). Thus, despite 
having similar clinical anticonvulsant ef- 
ficacy, their mechanisms of action are un- 
doubtedly dissimilar. 
To investigate the clinically relevant ac- 
tions of PT it is necessary to determine the 
concentration of PT in the central nervous 
system when serum levels are in the 
therapeutic range. PT is a lipid soluble 
compound that is highly protein bound 
(-90%). At therapeutic serum levels 
(10-20 yglml or 40-80 p M ) ,  free-serum PT 
levels are about 1-2 pglml (4-8 y M ) .  
Cerebrospinal fluid levels are equal to 
free-serum levels, but brain concentrations 
are variable and range from 75 to 120% of 
total serum concentration (49). Thus, 
does PT have its relevant actions at total 
serum, free-serum, or .brain concentra- 
tions? As one approach to this issue, we 
determined the dose-dependency of PT ac- 
tions on spontaneous activity and on 
convulsant-induced paroxysmal activi- 
ty recorded from mouse spinal cord neurons 
in cell culture (50). When added to the 
protein-free bathing medium, PT did not al- 
ter normal spontaneous activity at concen- 
trations up to 2 pg/ml (Fig. 5). However, 
above 2 pg/ml, there was a progressive re- 
duction in spontaneous activity and an in- 
crease in the percentage of neurons with no 
spontaneous activity. At 5 pg/ml, about 50% 
of neurons were quiescent. Based on these 
results, it is unlikely that PT has its clin- 
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FIG. 5 .  Phenytoin reduced spontaneous activity. 
Phenytoin produced a dose-dependent increase in the 
number of quiescent neurons. However, at or below 2 
pLgiml, PT did not alter spontaneous activity. 
ical action at  brain or total serum con- 
centrations, since all spontaneous activity 
would be suppressed. Thus, it is likely that 
the free-serum (and cerebrospinal fluid) 
levels of 1-2 pg/ml are the relevant con- 
centrations. 
If free-serum concentrations of PT are 
relevant for anticonvulsant action, what 
effect does PT have on convulsant-induced 
paroxysmal activity at these concentra- 
tions? At 2 pglml, PT did not suppress PDE 
PICRO 100clM 
(Fig. 6, top). The paroxysmal activity was 
often increased in frequency by PT. When 
higher concentrations of PT were used 
(5-20 pg/ml), PDE was suppressed in a 
dose-dependent fashion, but the paroxys- 
mal activity was replaced by quiescence 
(Fig. 6, bottom). Thus, unlike the barbitu- 
rates, PT does not act by suppressing 
convulsant-induced paroxysmal activity. 
How then does PT produce anticonvul- 
sant effects? Four basic actions of F'T have 
been described and proposed as the an- 
ticonvulsant mechanism of action (Table 
2). First, PT has been shown to reduce the 
rise in intracellular sodium produced by 
MES (51). Two alternative mechanisms for 
this have been proposed. PT and the inac- 
tive PT metabolite 5-hydroxyphenyl-5- 
phenylhydantoin (HPPH) enhance Na-K 
ATPase activity (5233) (and therefore pre- 
sumably increase active extrusion of 
sodium ions) by reducing the inhibitory ef- 
fect of high sodium concentrations. How- 
ever, this effect was not specific for PT, 
since HPPH was also active (53). Thus, it is 
unlikely that PT has anticonvulsant action 
by enhancing active sodium extrusion. Al- 
ternatively, PT has been shown to reduce 
the maximal rate of rise, overshoot, and 
+ P T  
FIG. 6. Phenytoin (PT) did not suppress paroxysmal depolarizing events (PDE) at therapeutic free-serum 
concentrations. PDE were produced by addition of 100 p M  picrotoxin (PICRO) to phosphate buffered saline 
bathing medium. PT at 2 pg/ml did not suppress PICRO-induced PDE (top) but did suppress PDE at 20 pdml 
(bottom). Intracellular recordings were made with micropipettes containing 4 M potassium acetate. 
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TABLE 2. Phenytoin actions 
Reduction of nonsvnaptic sodium ion movements 
Enhancement of active sodium ion transport 
Reduction of sodium ion channel conductance 
Reduction of preJynuptic calcium ion entry and neurotransmitter release 
Alteration of postsynaptic neurotrammitter action 
Enhancement of GABA-mediated inhibition 
Antagonism of excitatory synaptic transmission 
Reduction of repetitive firing and posttetanic potentiation 
amplitude of sodium-dependent action po- 
tentials (54-57) and to  decrease inward 
sodium ion fluxes (58,59). Second, PT has 
been shown to reduce calcium-dependent 
potentials (60), to reduce inward calcium 
fluxes (61-63), and to reduce presynaptic 
release of neurotransmit ters  (64-67). 
Third, PT has been shown to modify post- 
synaptic neurotransmitter responses. PT 
enhanced postsynaptic GABA responses in 
the crayfish stretch receptor neuron (68,69) 
as  well as cortical inhibition in the cat (70). 
However ,  PT did not a l ter  GABA re- 
sponses evoked on rat dorsal root ganglion 
neurons (71) nor on rat hippocampal pyra- 
midal neurons (72). PT reduced excitatory 
postsynaptic responses to acetylcholine at  
the neuromuscular junction (67) and the ex- 
citatory actions of glutamate and acetyl- 
choline in rat cortex (73). Finally, PT has 
been shown to  reduce repetitive firing 
(74-76) of neurons, nerve terminals, and 
muscle cells, and to  reduce posttetanic 
potentiation (76,77) evoked in cat  spinal 
cord and sympathetic ganglia. 
Using spinal cord neurons in cell culture, 
we studied several of these actions of PT to 
determine which were produced at low PT 
concentrations (1-2 pg/ml) (50). PT re- 
duced the maximum rate of rise of sodium- 
dependent action potentials (an index of 
inward sodium current) and reduced the du- 
ration of calcium-dependent action poten- 
tials (an index of inward calcium current) 
only at PT concentrations above 2.5 pglml. 
The reduction of action potentials corre- 
lated with reduction of spontaneous activ- 
ity. GABA and glutamate responses were 
not altered by PT at 2 pglml. Thus, it is 
unlikely that PT has anticonvulsant action 
by blocking sodium channels or  calcium 
channels o r  by modulating postsynaptic 
GABA responses. However, repetitive fir- 
ing produced by depolarizing currents was 
substantially reduced by PT at 1-2 pg/ml 
(Fig. 7). In control medium, a 2-s depolari- 
zation of sufficient amplitude evokes a 
continuous train of action potentials. PT at  
0.2 pg/ml did not modify this firing pattern 
(Fig. 7A). However, PT at 1.0 and 2.0 pglml 
reduced the duration of repetitive firing 
dose-dependently (Fig. 7B and C). HPPH at 
10 pglml did not modify repetitive firing 
(Fig. 7D). The effect of PT on repetitive 
firing was fully reversible following wash- 
out  of the  PT.  Thus ,  PT may have  an- 
t iconvulsant  activity due  t o  i ts  ability 
to limit high frequency repetitive firing, a 
characteristic firing pattern in epileptogenic 
foci. The mechanism by which PT produces 
this limitation of repetitive firing is uncer- 
tain and is currently under investigation. 
Possibilities include (a) a shift of the voltage- 
dependency of slow inactivation of sodium 
channels, (b)  reduction in the rate of re- 
moval of sodium channel inactivation, (c)  
development of use-dependent sodium chan- 
nel block, or (d)  enhancement or produc- 
tion of a slow outward calcium- or voltage- 
dependent potassium conductance. 
Conclusions 
The results obtained thus far suggest that 
although barbiturates and phenytoin have 
multiple actions on neuronal membrane 
properties,  electrical  excitabil i ty,  and 
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FIG. 7. Phenytoin suppressed repetitive firing. Intracellular recordings were made from spinal cord neurons, 
and long (2.0 s) depolarizing current pulses were applied using the single electrode bridge technique. Re- 
cordings shown are photographs of oscilloscope traces (A-D). Continuous recordings were made from 
individual neurons prior to (PRE), during (FT) and following (POST) superfusion of hydantoin-containing bathing 
medium. The recordings in A-D were made from different neurons. See text for details. 
synaptic transmission, their specific anti- 
convulsant actions can be postulated to be 
postsynaptic modulation of neurotransmit- 
ter actions and suppression of repetitive 
firing, respectively. These conclusions 
should be considered as working hypoth- 
eses to be evaluated using more intact, 
vertebrate, central neuronal preparations 
such as hippocampal or neocortical slices in 
L9itvo or intact cortex in ~rivo. It is certainly 
possible that alternate mechanisms will be 
identified in the more intact preparations, 
but the investigation should be facilitated 
by comparisons to data obtained from 
mammalian neurons in cell culture. 
A clear objective of this research in the 
future is the identification of the therapeutic 
and toxic actions of all major anticonvul- 
sants using this in t,itvo preparation. Once 
these mechanisms are identified, it should 
be possible to study specific physiological 
actions of drug congeners to identify which 
portions of the drug molecules are relevant 
for each of the therapeutic and toxic drug 
actions. Furthermore, it should be possible 
to formulate specific drugs that would have 
improved therapeutic indices and therefore 
would be clinically more useful. Finally, it 
should be possible to study the interactions 
of anticonvulsants with different mecha- 
nisms of action to determine which drugs 
have synergistic anticonvulsant action 
without synergistic toxicity. 
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